Table 1. The characteristics of included studies in this study.

Study, year		Mori, 2009 [15]	Lee, 2011 [16]	Dai, 2011 [17]	Farsi, 2015 [18]	Sanoobar, 2015 [19]	Lee, 2013 [20]	Mohseni, 2015 [21]	Raygan, 2015 [22]	Nesami, 2015 [23]
Country		Australia	Korea	China	Iran	Iran	China	Iran	Iran	Iran
Duration (weeks)		8	12	8	12	12	12	12	8	12
Coenzyme Q10 dose (mg/d)		200	200	300	100	500	300	200	100	100
Health status		risk of CVD in chronic kidney disease	obesity	coronary artery disease	NAFLD	multiple sclerosis	coronary artery disease	myocardial infarction	metabolic syndrome	hypertension
Adverse effects		NR	NR	No	redness, itchiness	NR	No	NR	No	No
Age, years	CoQ10	55.4±2.7a	42.7±11.3a	67.7±9.4a	19–54b	33.1± 7.6a	71.7±11.5a	60.0±8.0a	65.9±12.5a	49.7±5.65a
	Placebo	58.6±2.6a	42.5±11.2a	70.1±9.8a	19–54b	30.9± 7.7a	66.5±11.1a	61.0±7.0a	59.9±13.1a	48.07±6.33a
Sample size	CoQ10	21	17	28	20	22	23	26	30	30
	Placebo	15	19	28	21	23	19	26	30	30
CoQ10,μg/mL (Mean±SD)	CoQ10	NR	0.58±0.24	1.08±0.41	NR	NR	NR*	NR	NR	NR
	Placebo	NR	0.65±0.27	0.95±0.29	NR	NR	NR*	NR	NR	NR
IL-6, pg/mL (Mean±SD)	CoQ10	NR	NR	NR	2.15± 0.98	1.52± 2.4	NR*	17.7±7.65	NR	NR
	Placebo	NR	NR	NR	2.19 ± 0.9	1.53± 2.2	NR*	12.61±5.91	NR	NR
TNF-α, pg/mL (Mean±SD)	CoQ10	NR	NR	NR	1.38 ± 0.71	6.2 ±0.97	NR*	NR	NR	NR
	Placebo	NR	NR	NR	1.27± 0.09	6.09±0.92	NR*	NR	NR	NR
CRP,mg/L (Mean±SD)	CoQ10	1.46±2.87	1.42±1.13	2.29±3.10	18.81 ± 6.96	NR	NR*	NR	1.51±1.57	3.53 ± 3.36
	Placebo	1.56±2.87	1.04±1.45	1.48±1.82	19.85 ± 9.14	NR	NR*	NR	2.91±3.05	4.12 ± 3.20

Note: CVD, cardiovascular disease; NAFLD: nonalcoholic fatty liver disease; CoQ10: Coenzyme Q10; IL-6: interleukin-6; TNF-α:tumor necrosis factor-alpha, CRP: C reactive protein; NR, not reported.

*the original basic data was not provided and the mean change was replaced;

^a, described as Mean±SD;

^b, described as minimums and maximums.